NEW YORK (GenomeWeb News) – Molecular diagnostics firm Veracyte today announced the final tranche of its Series C financing round raising $28 million.

Proceeds will go toward commercial expansion of its gene expression-based diagnostic tool called Afirma Thyroid FNA Analysis for thyroid cancer and the development of its product pipeline.

GE Ventures was a new investor in the round. Domain Associates, Kleiner Perkins Caufield & Byers, TPG Biotech, Versant Ventures, and all previous investors participated.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

PLOS Biology has asked researchers how they envision the future of genetics and genomics.

Representative Lamar Smith brings back a provision to require the National Science Foundation to certify that each study it funds is "in the national interest."

The US Food and Drug Administration has approved four molecularly targeted drugs this month, suggesting that personalized medicine has "turned a corner."

In Science this week: caution urged in use of gene drives, and more.